Ohh-Medical
Home Medical Device for Improving Erectile Function and Treating Erectile Dysfunction
Company Overview
Snapshot
Founded in February 2017 by Daniel Lischinsky, Ohh-Medical operates with 1–10 employees. The company has secured funding across one round from Arbelon Holdings Ltd. In June 2024, Ohh-Med Medical unveiled its VerticaPlus device, designed for the treatment of erectile dysfunction.
Business overview
Ohh-Medical is a medtech company specializing in innovative medical solutions for men's health. The company develops, manufactures, and markets patented medical devices to address urological conditions, including erectile dysfunction (ED). Its flagship product, Vertica, is a non-invasive, prescription-free, and side-effect-free home-use device that utilizes medical-grade radiofrequency technology to restore natural erectile mechanisms by improving collagen quality in penile tissues. Ohh-Medical targets both consumer and professional healthcare markets, operating within the Health Tech & Life Sciences sector.
Strategic signal
In June 2024, Ohh-Med Medical unveiled its VerticaPlus device for erectile dysfunction. This product launch indicates the company's continued innovation and expansion within the men's health market, signaling a strategic focus on enhancing its product portfolio and addressing a significant medical need with advanced, non-invasive solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is Ohh-Medical's core product?
- Ohh-Medical's core product is Vertica, a non-invasive, prescription-free medical device designed for home use to improve erectile function and treat erectile dysfunction using medical-grade radiofrequency technology.
- When did Ohh-Medical launch its VerticaPlus device?
- Ohh-Med Medical unveiled its VerticaPlus device for erectile dysfunction in June 2024.
- Has Ohh-Medical received regulatory approvals for its products?
- Yes, Vertica received European CE MDR approval to market in Europe in 2023, and in 2021, the company received approval to market Vertica in Israel.
- What was a key finding from a pilot clinical study of Vertica?
- A pilot clinical study conducted at the Neuro-Urology unit, Rambam Healthcare Campus, showed that 25 out of 28 patients (85% success rate) experienced significant improvement in their erectile function after treatment with Vertica.
- Which investor participated in Ohh-Medical's funding round?
- In May 2020, Ohh-Medical secured seed funding from Arbelon Holdings Ltd.